Download here - Pelago Bioscience

PE L AG O BI OS CI ENCE NEWS / SPRING 2017
Pelago celebrated
its 4th Birthday on
February 28th 2017
It has been an exciting and successful first 4 years
2013
Company formed,
publication of the
CETSA method in
Science (Martinez
Molina et al).
First customer and
first repeat customer.
UK patent granted.
2014
First sub-licenses
issued.
First 10 customer
projects completed.
First publication of
CETSA HT and
CETSA MS methods.
US patent granted.
2015
2016
Established the first
strategic collaboration
with global
pharmaceutical
company AstraZeneca
to benchmark the
utility in preclinical drug
discovery and screening.
European and other
patents granted.
More than 20 individual
customer accounts.
Moved to new
purpose built offices
& state of the art
CETSA laboratories.
First publications by
customers (Pfizer
& AstraZeneca)
Read more.
Completed 100
projects with more
than 30 different
companies.
2017
Pelago continues to
expand, with expected
completion of over
200 projects with
50 companies.
New collaborations
In January we announced that Pelago Bioscience
and Sygnature Discovery will collaborate to
provide CETSA® based Target Engagement assays
to their customers. Sygnature is the UK’s largest
independent provider of integrated drug discovery
resource and expertise. The collaboration will
effectively facilitate the integration of CETSA
assays for hit confirmation, lead profiling and
biomarker discovery in Sygnature projects.
Read full details.
Building on Success
In a new collaboration with the Karolinska Institute
we will build on the expertise used to develop the
CETSA HT format and expand its application to
develop high throughput automated assays for key
signaling proteins important in cell proliferation and
metabolism. Read more.
CETSA HT delivers the same data as its
predecessor, CETSA Classics; but its plate based
format, fluorescence readout and significantly
lower price point make it a practical solution for
screening large numbers of compounds. Pelago
offers a CETSA HT assay development services.
Once established, the assay can either be run by
Pelago or transferred to the customer.
The CETSA MS project volume continues to
increase as the market appreciates the unique
opportunity to selectivity profile compounds
against whole proteomes, rapidly elucidating mode
of action. We are pushing the boundaries for the
analysis format of the 6000 protein profiling
campaigns to filter data quantitatively and rank
molecular hits on significance.
Conferences and meetings
AACR Annual meeting 2017,
Washington DC
1-5 APRIL 2017
ELRIG Advances in Cell based
Screening, Gothenburg
10-11 MAY 2017
Global Discovery To
Development Innovation
Forum, London
24-25 MAY 2017
Anglo-Nordic Medicinal
Chemistry Symposium,
Copenhagen
11-14 JUNE 2017
Oxford Global Drug
Discovery Summit, Berlin
CETSA user meeting 2017,
Stockholm
25-26 SEPTEMBER 2017
ELRIG Drug Discovery 2017,
Liverpool
3-4 OCTOBER 2017
12-13 JUNE 2017
NLSDays 2017,
Malmö
12-14 SEPTEMBER 2017
To me the combination of CETSA with mass spectrometry
is the most exciting thing that has happened in drug
discovery and proteomics in a long time.
Mikhail Savitski, Head of the Proteomics Core Facility at EMBL Heidelberg
PELAGO BIOSCIENCE NEWS
SPRING 2017